Leptin levels in patients with psoriasis: a meta-analysis


  • Conflict of interest: none declared.
  • The first three authors contributed equally to this work, and should be considered joint first authors.

Correspondence: Dr Kun-Ju Zhu, Department of Dermatology, Affiliated Hospital of Guangdong Medical College, 57, Remnin Avenue, Xiashan district, Zhanjiang, Guangdong, 524001, China

E-mail: zhukunju1111@163.com



There have been inconsistent results reported for leptin levels in patients with psoriasis.


To evaluate leptin levels in patients with psoriasis using a meta-analysis of studies comparing leptin levels in controls and in patients with psoriasis.


PubMed (MEDLINE), EMBASE and the Cochrane Library were searched for relevant papers published in English. Pooled weighted mean differences (WMDs) and 95% CIs were calculated using random-effects and fixed-effects models. Heterogeneity between studies was assessed using the Cochran Q and I2 statistics.


In total, 11 studies, comprising 773 patients with psoriasis and 570 healthy controls, were identified. Leptin levels were significantly higher in patients with psoriasis compared with controls (WMD = 7.24, 95% CI 4.55–9.93; < 0.001). On stratified analysis, significant differences in leptin levels between patients with psoriasis and controls were reported only in serum samples (< 0.001), and not in plasma samples (= 0.025). Sensitivity analysis showed that there were no changes in the direction of effect when any one study was excluded. No publication bias was detected.


Leptin levels are higher in patients with psoriasis compared with those in controls. Future studies are warranted to clarify the association between leptin levels and the pathomechanism of psoriasis.